Optimal Antihypertensive Selection in Emphysema

Primary Antihypertensive Recommendations

The European Society of Cardiology recommends calcium channel blockers (CCBs) or ACE inhibitors/ARBs as the preferred first-line antihypertensive agents for patients with emphysema and hypertension, as they effectively lower blood pressure without interfering with respiratory function 1
The American Heart Association suggests that ACE inhibitors or ARBs can be used safely and are particularly beneficial if the patient develops comorbid conditions like heart failure or chronic kidney disease 1, 2
The European Society of Cardiology states that thiazide or thiazide-like diuretics are acceptable options that effectively control blood pressure without respiratory complications 1

The American College of Cardiology recommends avoiding non-selective beta-blockers in emphysema/COPD as they can precipitate bronchospasm and worsen airflow obstruction 2
The American Heart Association suggests that cardioselective beta-blockers (bisoprolol, metoprolol succinate, carvedilol) may be considered only if there is a compelling indication such as heart failure with reduced ejection fraction or post-myocardial infarction, but require careful monitoring 2, 3

The European Society of Cardiology recommends targeting systolic blood pressure to 130-139 mmHg in most patients with COPD and hypertension 1
The American College of Cardiology suggests targeting systolic blood pressure to <130 mmHg in patients under age 65, if tolerated, but not below 120 mmHg 1
The European Society of Cardiology states that for patients ≥65 years, systolic BP should be maintained in the 130-139 mmHg range to balance cardiovascular protection with tolerability 1

The American Thoracic Society recommends starting with a long-acting muscarinic antagonist (LAMA) such as tiotropium as the foundation of COPD management, as LAMAs are superior to short-acting bronchodilators and preferred for exacerbation prevention 4
The American College of Chest Physicians suggests that for persistent breathlessness, a long-acting beta-agonist (LABA) should be added to create dual bronchodilator therapy (LABA/LAMA combination), which provides superior symptom control compared to monotherapy 4

The American Thoracic Society recommends against using drugs approved for primary pulmonary arterial hypertension (such as phosphodiesterase-5 inhibitors, endothelin receptor antagonists, or prostacyclins) in patients with pulmonary hypertension secondary to COPD, as these are not recommended and lack proven benefit 4, 5

The American College of Cardiology recommends never prescribing non-selective beta-blockers (propranolol, carvedilol in high doses) as they will worsen bronchospasm 2
The American Thoracic Society suggests avoiding using pulmonary vasodilators empirically for mild pulmonary hypertension in emphysema without specialist consultation, as they are contraindicated in WHO Group 3 pulmonary hypertension 4, 5
The American Heart Association recommends not withholding cardioselective beta-blockers if the patient develops heart failure with reduced ejection fraction, as the mortality benefit outweighs respiratory concerns when carefully titrated 2, 3